Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Cash from Operations (2024 - 2025)

Allarity Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 3243000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 1.15% year-over-year to 3243000.0; the TTM value through Dec 2025 reached 14820000.0, up 14.59%, while the annual FY2025 figure was 14820000.0, 14.59% up from the prior year.
  • Cash from Operations reached 3243000.0 in Q4 2025 per ALLR's latest filing, up from 3410000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1399000.0 in Q1 2024 to a low of 7304000.0 in Q2 2024.